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Introduction
Drug development is a complex and costly process with high
attrition. Of the terminated drug candidates, the majority fails
because of lack of efficacy and safety [1,2]. Efficacy and safety
are tested in preclinical experiments, but to improve success
rates, interspecies translation needs to move from an empirical
to a mechanistic approach [3]. Systems pharmacology is such
an approach, combining the strengths of systems biology and
pharmacometrics [4]. Understanding the systems of species
and their differences helps improving interspecies translation
of efficacy and safety data. In this review, we will focus on
systems pharmacology of hepatic function and dysfunction,
and the importance of understanding the drug exposure over
time in a biological system. The unique position of zebrafish
larvae as vertebrate model organism for systems pharmacolo-
gy with high-throughput potential will be discussed.
Systems pharmacology: integrating pharmacometrics
and systems biology
Systems pharmacology is a method to contribute to transla-
tional medicine by integrating modelling and simulation in zebraﬁsh larvae, Drug Discov Today: Dis Model (2017), http://dx.doi.org/10.1016/j.
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/). http://dx.doi.org/
e1
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‘systems level’ mechanistic way, improving interspecies
translation of relevant biological processes [5]. Systems phar-
macology originates from two established fields, pharmaco-
metrics and systems biology, and aims to quantify the
pharmacological perturbations of the biological system of
an organism to improve our understanding of the interaction
between a drug and a particular biological system.
Pharmacometrics aims to predict drug effects using math-
ematical models to quantify interactions between organisms
and pharmaceutical compounds [6]. This results in pharma-
cokinetic-pharmacodynamic (PK-PD) models integrating
drug pharmacokinetics, which describes drug exposure as
concentration versus time, and drug pharmacodynamics,
which describes effects versus drug concentration. A sche-
matic of a PK-PD model can be seen in Fig. 1. Observed
outcome measures (i.e. concentrations and effects) are de-
scribed by mathematical equations, from which the underly-
ing primary model parameters are derived. After evaluation of
the predictive performance of a model, the model can be used
for predictions and to improve interspecies translation of
drug pharmacokinetics and pharmacodynamics and to de-
sign treatment regimens in both preclinical and clinical
studies [7].
Systems biology studies the structure and dynamics of
integrated biological systems to understand processes that
are too complex to intuitively comprehend by studying its
isolated elements only. Like pharmacometrics, this requires
quantitative data as well as advanced computational model-
ling [8]. Systems biology as holistic approach has the advan-
tage of placing part of a system in the biological context of a
complete organism. Characterising individual parts of thePlease cite this article in press as: van RC, et al. Systems pharmacology of hepatic metabolism
ddmod.2017.04.003
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e2 www.drugdiscoverytoday.comsystem, like gene or protein function, from in vitro experi-
ments is an important first step [8]. The next step is to
elucidate the interaction of these parts in the network of
the whole system. This is relevant in for example disease
models, as most diseases are not – as previously believed –
caused by a single target, for which a single drug can be
designed [9]. In contrast to in vitro experiments with human
cells only, an in vivo whole organism experiment can identify
compounds able to treat or cure such a disease [10]. Using
these complementary experimental data to inform the sys-
tems biology model, the understanding of the biological
processes in the organism improves, and with it the under-
standing of how systems differ between species. This may
improve interspecies translation.
Zebraﬁsh larvae as vertebrate model organism in drug
development
Systems biology models have been developed in invertebrate
organisms, such as yeast (Saccharomyces cerevisiae), round-
worms (Caenorhabditis elegans) and fruit flies (Drosophila)
[11]. These small organisms are easily genetically modified
and allow for high-throughput measurements [11]. However
in pharmacological studies, a vertebrate species is believed to
have improved translational potential due to its increased
genetic homology to mammals. The zebrafish (Danio rerio) is
such a vertebrate model organism that is increasingly used as
a model for biomedical studies [12]. Most genes coding for
essential proteins such as those in xenobiotic metabolism are
evolutionary conserved. Of human and murine genes, 70%
and 71% respectively have a zebrafish orthologue [13]. For
comparison, 83% of human genes have a murine orthologue
[13]. When considering genes for which defects can cause in zebraﬁsh larvae, Drug Discov Today: Dis Model (2017), http://dx.doi.org/10.1016/j.
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[14]. Human disease models in zebrafish larvae have been
validated for hyperlipidaemia, liver steatosis, cancer, and
mycobacterium infections, among others [15–17].
The use of zebrafish larvae in drug development is increas-
ing because of its many advantages [12]. The four most
relevant advantages for drug development include high fe-
cundity, fast development, optical transparency, and easy
genetic modification.
Zebrafish have a high reproduction rate. One pair of adult
fish yields 100–200 fertilised eggs per mating, reaching up to
10,000 eggs per year. Adults are small (3–5 cm) and are
housed in groups of on average 5–13 fish per litre [18]. This
combination of fecundity and size results in large numbers of
larvae and fish at limited costs [19].
After external fertilisation, the embryo develops in its
chorion until hatching between 48–72 h post fertilisation
(hpf), reaching the larval stage. At that time, the development
of most organs is nearly complete, except for the organs in the
gastro-intestinal (GI) tract [20]. After 76 hpf, the liver, pan-
creas, and gut are fully developed, and at 96 hpf, the GI tract is
completely open [21]. Experiments are generally performed
in the larval phase when the fish are largely developed but
small enough (3–5 mm) to fit in multi well plates up to 384
well format.
Zebrafish are optically transparent during early embryonic
and larval stages, enabling non-invasive in vivo optical imag-
ing of anatomical and certain (patho)physiological develop-
ments. Because it is not required to sacrifice the fish, effects
can be observed by microscopy over time in a single subject.
An example is the phenotypic assay that has been developed
to screen for hepatotoxicity by imaging of liver size, yolk size,
and liver degeneration [22]. If automated, these assays have
the potential to reach throughput rates of 1000–10,000 assays
per day [19].
Forward and reverse genetic modification of the zebrafish is
especially easy because the external fertilisation allows injec-
tions of the single cell zygote. Genetic modification enables
studying gene mutations, as well as mechanisms of action of
compounds [11]. It is also possible to humanise zebrafish with
human enzymes [23]. Transgenic lines have been developed,
expressing fluorescent reporter proteins under control of a
wide variety of promoter sequences specific for particular cell
types [24]. Due to the transparency of the larvae, both gene
expression and function can be examined spatially and over
time using fluorescence microscopy [25].
In short, large numbers of fast developing subjects with
relevant genetic modifications can be achieved with the
potential of automated high-throughput screening in num-
bers suitable for meaningful statistical analysis [26,27]. More-
over, it is from an ethical perspective best to perform animal
experiments – if at all necessary – in the available model
organism that is least developed [21]. The zebrafish larvaePlease cite this article in press as: van RC, et al. Systems pharmacology of hepatic metabolism
ddmod.2017.04.003model organism thus combines ethical and practical advan-
tages with the increased homology to higher vertebrates,
compared to invertebrates.
Drug exposure drives effects
For translation of drug effects between species it is not just
systems biology and homology of drug targets that are im-
portant. The internal exposure of an organism to a drug and
its metabolites over time is what drives the drug effects.
Quantifying internal exposure is necessary to prevent false
positives and negatives [28]. Deriving exposure-response rela-
tionships for both desired effects and adverse effects is there-
fore absolutely essential for interspecies translation of drug
pharmacology and toxicology of the parent compound and
metabolites. Unfortunately, this is almost always overlooked
in pharmacological and toxicological screens with zebrafish
larvae. In addition to deriving exposure-response relation-
ships, information on the internal exposure over time in
these larvae provides valuable knowledge needed for transla-
tion of drug pharmacokinetics from this small vertebrate to
higher vertebrates like rodents, monkeys, and even humans,
with all their physiological differences. As drug pharmacoki-
netics drive the dose-exposure relationship, translating it can
significantly improve (pre)clinical experimental design by
informing dosing rationale.
Internal exposure is quantified by describing the pharma-
cokinetic processes absorption, distribution, metabolism,
and excretion (ADME) of drugs. Drug elimination by metab-
olism and excretion is quantified as clearance, which is the
most important determinant of drug exposure. Metabolism
of xenobiotics, including drugs, increases hydrophilicity to
improve renal excretion and mostly occurs in the liver. Phase
I metabolism is of catabolic nature. Xenobiotics are oxidised,
reduced, or hydrolysed. Cytochrome P450 (CYP) enzymes are
the most important enzymes in catalysing phase I reactions.
Phase II metabolism, also known as conjugation, is anabolic
and includes transfer of a hydrophilic moiety from a donor to
the xenobiotic. Examples of enzymes catalysing conjugating
reactions are sulphotransferases (SULTs) and UDP-glucuro-
nosyltransferases (UGTs), amongst others. Drug metabolism
can result in reactive metabolites, which may cause toxicity
in the metabolising organ [29].
Hepatic metabolism in the zebraﬁsh
A mechanistic understanding of drug metabolism by a pre-
clinical species in relation to human metabolism requires
comparison of both amino acid sequence and function of the
responsible enzymes. Table 1 shows the relationship of a
selection of metabolising enzymes in zebrafish with their
corresponding enzymes in humans. These relationships are
orthologous, descending from a common ancestral sequence,
unless otherwise specified. Specific focus is on the enzymes
responsible for paracetamol (Box 1) metabolism. in zebraﬁsh larvae, Drug Discov Today: Dis Model (2017), http://dx.doi.org/10.1016/j.
www.drugdiscoverytoday.com e3
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Table 1. A selection of metabolising enzymes of zebraﬁsh and their human homologues. Enzymes involved in paracetamol
metabolism are printed in italics.
Enzyme family Zebraﬁsh enzyme Human enzyme Ref.
CYP1 CYP1Aa CYP1A1/1A2 [30]
CYP1B1b CYP1B1 [30]
CYP1D1 CYP1D1Pc [30]
CYP1C1,2 – [30]
CYP2 CYP2AD2,3,6, CYP2N13, CYP2P1-6, CYP2V1 CYP2J2 [30]
CYP2K1-8 CYP2W1 [30]
CYP2R1 CYP2R1 [30]
CYP2U1 CYP2U1 [30]
CYP2Y3,4 CYP2A6,13/B6/F1/S1 [30]
CYP2Y3b, CYP2P6b CYP2E1 [52]
CYP2AA1-12 – [30]
CYP2AE1,2 – [30]
CYP2X1-10 – [30]
CYP3 CYP3A65 CYP3A4 [30,31]
CYP3C1d CYP3A4 [53]
CYP3C1-4 CYP3A-se1c, -se2c [30]
CYP4 CYP4F43 CYP4Vs [30]
CYP4T8 – [30]
SULT1 SULT1ST2d SULT1A1 [34]
SULT1ST5b SULT1B1 [54,55]
SULT1ST6b SULT1E1 [54,55]
SULT1ST9b, SULT3ST1d SULT1A3 [36,56]
SULT4 SULT4A1b SULT4A1 [57]
UGT1 UGT1e UGT1 [37,58]
UGT2 UGT2e UGT2 [37,58]
UGT5 – [37]
a Similar exon structure.
b Similar gene structure.
c Pseudogene.
d Based on function or substrate speciﬁcity.
e Paralogous relationship.In humans, the most important CYP enzyme isoforms in
drug metabolism are CYP3A4 and CYP2E1. CYP3A4 has at
least one orthologue in zebrafish, namely CYP3A65 which is
54% identical in amino acid sequence as well as being iden-
tical in function [30,31]. Zebrafish CYP2Y3 and CYP2P6 are
both 43% identical to human CYP2E1 in amino acid se-
quence [32].
Several human SULTs have orthologues in zebrafish, main-
ly from the SULT1 family [33]. Zebrafish SULT1ST2 shows
similar xenobiotic sulphation as human SULT1A1, although
no gene orthology has been established [34]. Human
SULT1A3 is 49% identical in amino acid sequence to zebrafish
SULT1ST9 [35]. Although no clear homology has been found
between zebrafish SULT3ST1 and human SULT1A3, this en-
zyme is responsible for xenobiotic sulphation similar to
SULT1A3 [36].
For human and zebrafish UGT enzymes, no orthologous
relationships have been found. Instead, these enzymes are so
called paralogues, of which the common ancestral gene has
been duplicated with different genes in zebrafish and mam-
mals as a result [37]. Despite less genetic overlap than ortho-
logues, paralogues can still have comparable metabolicPlease cite this article in press as: van RC, et al. Systems pharmacology of hepatic metabolism
ddmod.2017.04.003
e4 www.drugdiscoverytoday.comfunction. For paracetamol (Box 1) the glucuronide-metabo-
lite that is abundantly formed in humans, has been observed
in zebrafish larvae as well [38].
Quantifying metabolising function of the liver
To quantify the metabolising function of hepatic enzymes,
pharmacometrics uses for instance non-linear mixed effects
modelling to develop empirical compartmental models that
quantify pharmacokinetics of drugs in blood, based on con-
centration-time data. This is the biggest challenge of the
zebrafish larvae as model organism for systems pharmacolo-
gy-based translation of drug pharmacology, as quantifying
internal drug and metabolite exposure over time in such
small organisms is difficult [12,39]. Currently the external
drug concentration in the medium surrounding the larvae is
most often used as predictor of the internal drug concentra-
tion. It has been tried to predict internal exposure or toxicity
based on physicochemical properties of compounds such as
hydrophilicity, but without success [40–42]. Only recently,
our group developed a sensitive liquid chromatography-mass
spectrometry (LC/MS) method to quantify internal exposure
of paracetamol (Box 1) as a model compound, which resulted in zebraﬁsh larvae, Drug Discov Today: Dis Model (2017), http://dx.doi.org/10.1016/j.
Vol. xxx, No. xx 2017 Drug Discovery Today: Disease Models |
DDMOD-451; No of Pages 8
Box 1. Model drug paracetamol
Paracetamol (Fig. 2), also known as acetaminophen, is a widely used analgesic [59]. Paracetamol is metabolised in the liver by both phase I and phase II enzymes,
and to a limited amount excreted unchanged (<5%). Sulphation by sulphotransferases SULT1A1 and SULT1A3 and glucuronidation by urine 5’-diphospho-
glucuronosyltransferase UGT1A6 are responsible for 85% of its metabolism in human adults. The remaining parent compound is oxidised, mainly by
cytochrome P450 CYP2E1 to N-acetyl-p-benzoquinone imine (NAPQI), and to a lesser extent by CYP2A6 to methoxy-paracetamol. NAPQI is a toxic
metabolite, which reacts with antioxidant glutathione (GSH) to form the nontoxic metabolites cysteine- and mercapturate-paracetamol, among others. At
supratherapeutic doses, GSH reserves are depleted and oxidative stress results in hepatotoxicity [60].
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Figure 2. Chemical structure of paracetamol and its major metabolites.in the first pharmacokinetic model in zebrafish larvae [38].
This model quantified exposure over time of the parent
compound, which can be linked to efficacy data. The esti-
mated parameter clearance was scaled between the zebrafish
larvae and 12 higher vertebrate species, including rodents,
monkeys, and humans, showing reasonable comparability.
The model can be extended to include paracetamol majorPlease cite this article in press as: van RC, et al. Systems pharmacology of hepatic metabolism
ddmod.2017.04.003metabolites and their formation rates catalysed by phase I
and II enzymes.
Empirical interspecies scaling of paracetamol clearance to
higher vertebrates, including humans, was found to be rea-
sonable [38]. When developing new drugs, the clearance in
zebrafish might therefore also be used to scale to higher
vertebrates and optimise preclinical experimental designs. in zebraﬁsh larvae, Drug Discov Today: Dis Model (2017), http://dx.doi.org/10.1016/j.
www.drugdiscoverytoday.com e5
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kinetic translation, is the systems approach, where mecha-
nistic details on the metabolism can be included into the
model, such as the type of enzymes involved in metabolism
of a compound of interest. When the differences between the
enzymes of the species of interest are known, the mechanistic
model can inform the translation of the pharmacokinetics, in
a systems pharmacology approach. Additionally, pharmaco-
logically active metabolites can cause off-target (adverse)
effects. It is therefore important to establish if the same
metabolite species are formed in different vertebrates. If that
is the case, it is essential to quantify their exposure over time
to translate the exposure-response relationship of these ad-
verse effects.
Quantifying liver dysfunction
Hepatotoxicity is an important adverse effect of drugs. One
aim of drug screens in zebrafish larvae is to detect potential
toxicity issues. Hepatotoxicity assays in zebrafish have been
widely published [22,31,43]. This includes assessment of
histopathology and transcriptome profiling in zebrafish lar-
vae [44]. Internal drug and metabolite exposure causing this
toxicity needs to be quantified for proper interpretation and
translation. Moreover, hepatic dysfunction resulting from
this toxicity may impact drug clearance. This impact, and
its effect on the exposure-time profile, can be quantified using
a similar approach as described in Quantifying metabolising
function of the liver. The observed adverse effect is then linked
to the toxic compound or metabolite (Fig. 1). This provides
mechanistic insight in the influence of hepatic dysfunction
on the metabolism of both endogenous and exogenous
compounds, including drugs. Informed by the relevant sys-
tem-specific properties, a systems pharmacology model can
translate these findings to mammalian model organisms, and
humans.
The validity of a pharmaco- or toxicodynamic model
increases with the use of mechanistic biomarkers that de-
scribe the disease state, in this case hepatic dysfunction [7].
Mechanistic models describe (patho)physiological processes
that are important between drug administration and its
intended or adverse effect. Biomarkers can be used to charac-
terise and quantify these processes [45]. Alanine aminotrans-
ferase (ALT) and aspartate aminotransferase (AST) are for
example widely used hepatotoxicity markers in the clinic.
A useful biomarker is both specific and sensitive. ALT is
however not liver specific, being expressed in cardiac, renal,
and muscle tissue in addition to hepatic tissue [46]. Moreover,
it has a delayed response to liver injury, and may not always
correlate with clinical symptoms [47,48]. The novel biomark-
er miRNA-122 has been shown to be a more accurate and
time-sensitive alternative to indicate hepatotoxicity in both
preclinical and clinical settings [49]. This biomarker has also
been studied in zebrafish [50].Please cite this article in press as: van RC, et al. Systems pharmacology of hepatic metabolism
ddmod.2017.04.003
e6 www.drugdiscoverytoday.comFinally, there lies an opportunity for the objective quanti-
fication of organ size in zebrafish larvae. Transgenic zebrafish
lines with fluorescent organs are available, enabling studying
many organs and their development. A reproducible and
automated method is the Vertebrate Automated Screening
Technology (VAST). In short, complete larvae are withdrawn
from a well plate or tube and flow through a capillary linked
to a microscope, which captures images of the larvae from
different angles in an automated manner. These images can
then be processed using 3D silhouette modelling to calculate
the volume of the larva [51]. Using this method, we have not
only determined the volume of the zebrafish larva at different
hpf, but also the volume of its liver [unpublished results]. This
combination of techniques can be used to observe toxic
effects on organ size. Reversely, it can be used to create a
database of organ properties and their development. These
system specific properties can then be linked to pharmacoki-
netic parameters to inform systems pharmacology or physi-
ology-based pharmacokinetic (PBPK) models.
Conclusions
Systems pharmacology, integrating pharmacometrics with
systems biology, has the potential to improve interspecies
translation of pharmacological findings, and thereby drug
development. The zebrafish larva is a promising pre-clinical
model organism in systems pharmacology, combining high-
throughput potential within a vertebrate species. Drug meta-
bolising enzymes are comparable and metabolic rates can be
derived by combining sensitive LC/MS methods and mathe-
matical modelling. Comparable to quantifying liver func-
tion, other (patho)physiological processes, for example
liver dysfunction, can also be quantified. Pivotal for proper
interpretation of these experimental pharmacological find-
ings is characterising the internal drug exposure, which can
then be linked to the observed response in an exposure-
response relationship needed for interspecies scaling. More
emphasis on the pharmacokinetics is therefore required for
this species to change the course of drug development in the
future.
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